» Articles » PMID: 36203419

Radiomics-based Nomogram As Predictive Model for Prognosis of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Receiving Radiotherapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Oct 7
PMID 36203419
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aims to establish and validate a predictive model based on radiomics features, clinical features, and radiation therapy (RT) dosimetric parameters for overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with RT for portal vein tumor thrombosis (PVTT).

Methods: We retrospectively reviewed 131 patients. Patients were randomly divided into the training ( = 105) and validation ( = 26) cohorts. The clinical target volume was contoured on pre-RT computed tomography images and 48 textural features were extracted. The least absolute shrinkage and selection operator regression was used to determine the radiomics score (rad-score). A nomogram based on rad-score, clinical features, and dosimetric parameters was developed using the results of multivariate regression analysis. The predictive nomogram was evaluated using Harrell's concordance index (C-index), area under the curve (AUC), and calibration curve.

Results: Two radiomics features were extracted to calculate the rad-score for the prediction of OS. The radiomics-based nomogram had better performance than the clinical nomogram for the prediction of OS, with a C-index of 0.73 (95% CI, 0.67-0.79) and an AUC of 0.71 (95% CI, 0.62-0.79). The predictive accuracy was assessed by a calibration curve.

Conclusion: The radiomics-based predictive model significantly improved OS prediction in HCC patients treated with RT for PVTT.

Citing Articles

Research progress of MRI-based radiomics in hepatocellular carcinoma.

Xie X, Chen R Front Oncol. 2025; 15:1420599.

PMID: 39980543 PMC: 11839447. DOI: 10.3389/fonc.2025.1420599.


Development and verification of a nomogram for predicting portal vein tumor thrombosis in hepatocellular carcinoma.

Liu G, Long J, Liu C, Chen J Am J Transl Res. 2025; 16(12):7511-7520.

PMID: 39822560 PMC: 11733390. DOI: 10.62347/PLQF5135.


Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence.

Li Y, Fan N, He X, Zhu J, Zhang J, Lu L J Hepatocell Carcinoma. 2024; 11:1429-1438.

PMID: 39050809 PMC: 11268770. DOI: 10.2147/JHC.S474922.


CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.

Cheng S, Hu G, Jin Z, Wang Z, Xue H Eur Radiol. 2023; 33(12):8715-8726.

PMID: 37436507 DOI: 10.1007/s00330-023-09830-7.


Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.

Dercle L, Yang M, Gonen M, Flynn J, Moskowitz C, Connors D Eur Radiol. 2023; 33(12):9254-9261.

PMID: 37368111 DOI: 10.1007/s00330-023-09862-z.


References
1.
Addario L, Tritto G, Cavaglia E, Amodio F, Giannelli E, Di Costanzo G . Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis. 2010; 43(4):319-24. DOI: 10.1016/j.dld.2010.09.003. View

2.
Zhang Z, Lai E, Zhang C, Yu H, Liu Z, Wan B . The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015; 20:8-16. DOI: 10.1016/j.ijsu.2015.05.009. View

3.
Yan M, Wang W . A radiomics model of predicting tumor volume change of patients with stage III non-small cell lung cancer after radiotherapy. Sci Prog. 2021; 104(1):36850421997295. PMC: 10453712. DOI: 10.1177/0036850421997295. View

4.
Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C . A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51(4):1274-83. DOI: 10.1002/hep.23485. View

5.
Yang B, Ji H, Zhong J, Ma L, Zhong J, Dong H . Value of F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations. Front Oncol. 2020; 10:567160. PMC: 7686546. DOI: 10.3389/fonc.2020.567160. View